Pharmaceutical care for a case of fulminant type 1 diabetes with insulin allergy and positive insulin autoantibodies

doi:10.19803/j.1672-8629.20210758

Chinese Journal of Pharmacovigilance ›› 2022, Vol. 19 ›› Issue (12): 1376-1379.
DOI: 10.19803/j.1672-8629.20210758

Pharmaceutical care for a case of fulminant type 1 diabetes with insulin allergy and positive insulin autoantibodies

TANG Yan¹, WANG Jialin², ZHOU Jingya^3,4, ZHAO Weigang⁵, DU Boran⁶, HU Dandan⁷, YANG Liping⁸, YANG Yingying⁹, ZHAO Zhe^1,10, YUAN Tao^5,*

¹Department of Pharmacy, Peking Union Hospital, Chinese Academy of Medical Sciences, Beijing 100010, China;
²Department of Pharmacy, Jilin People’s Hospital, Jilin Jilin 132001, China;
³Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China;
⁴WHO 1Collaborating Center on Family Classification of Diseases, Beijing 100730, China;
⁵Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China;
⁶Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China;
⁷Department of Pharmacy, Air Force Hospital of Easter Theater Command, Nanjing Jiangsu 210002, China;
⁸Department of Pharmacy, Handan First Hospital, Handan Hebei 056000, China;
⁹Department of Pharmacy, Affiliated Hospital of Chengdu University, Chengdu Sichuan 610016, China;
¹⁰Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China

Received:2021-08-05 Online:2022-12-15 Published:2022-12-21

Abstract

Abstract: Objective To investigate the importance of medication adjustment and pharmaceutical care for a case of fulminant type 1 diabetes with insulin allergy and positive insulin autoantibodies. Methods Clinical pharmacists participated in the whole process of treatment, reviewed the related literature and offered recommendations according to the fluctuations of the patient’s blood glucose. Results The physicians and patient took the advice of the clinical pharmacists. The blood glucose of the patient was brought under control. Conclusion By using the intimate knowledge of pharmacy, clinical pharmacists can assist physicians in establishing the therapeutic regimen and performing pharmaceutical monitoring of the patient, which can help ensure rational drug use.

Key words: insulin allergy, insulin autoantibody, fulminant type 1 diabetes, pharmaceutical care

CLC Number:

TANG Yan, WANG Jialin, ZHOU Jingya, ZHAO Weigang, DU Boran, HU Dandan, YANG Liping, YANG Yingying, ZHAO Zhe, YUAN Tao. Pharmaceutical care for a case of fulminant type 1 diabetes with insulin allergy and positive insulin autoantibodies[J]. Chinese Journal of Pharmacovigilance, 2022, 19(12): 1376-1379.

References

[1] ZHOU ZG.Guidelines for diagnosis and treatment of type 1 diabetes in China[M]. Beijing:People’s Medical Publishing House(人民卫生出版社), 2012.
[2] FU J, SHI BY.Fulminant type 1 diabetes: A distinct subtype of type 1 diabetes mellitus[J]. J Formos Med Assoc, 2013, 112(6): 363-364.
[3] WANG O, PAN H, XIANG HD.A case of human insulin allergy[J]. Chinese Journal of Diabetes(中国糖尿病杂志), 2002, 10(5): 306-307.
[4] CHAKRABORTY PP, BISWAS SN, PATRA S.Faulty injection technique: a preventable but often overlooked factor in insulin allergy[J]. Diabetes Ther, 2016, 7(1): 163-167.
[5] JIN RC, HUANG J.Clinical characteristics and management of allergic reaction to insulin preparation[J]. Chinese Journal of Endocrinology and Metabolis(中华内分泌代谢杂志), 2013, 29(9): 1-4.
[6] WATANABE K, KUSUNOKI Y, KATSUNO T, et al.A case of type 1 diabetes mellitus with which localized insulin allergy was markedly alleviated by switching to insulin glulisine[J]. Acta Diabetol, 2016, 53(5): 845-848.
[7] BECKER RH, FRICK AD.Clinical pharmacokinetics and pharmacodynamics of insulin glulisine[J]. Clin Pharmacokinet, 2008, 47(1): 7-20.
[8] GARG SK, ELLIS SL, ULRICH H.Insulin glulisine: a new rapid-acting insulin analogue for the treatment of diabetes[J]. Expert Opin Pharmacother, 2005, 6(4): 643-651.
[9] WATANABE K, KUSUNOKI Y, KATSUNO T, et al.A case of type 1 diabetes mellitus with which localized insulin allergy was markedly alleviated by switching to insulin glulisine[J]. Acta Diabetol, 2016, 53(5): 845-848.
[10] ZHAO WG.Selection of fast insulin analogues in insulin pump therapy based on guidelines[J]. Drug Evaluation(药品评价), 2020, 17(9):1-3, 29.
[11] HOOGMA RP, SCHUMICKI D.Safety of insulin glulisine when given by continuous subcutaneous infusion using an external pump in patients with type 1 diabetes[J]. Horm Metab Res, 2006, 38(6): 429-433.
[12] MUNIR KM, DAVIS SN.The treatment of type 1 diabetes mellitus with agents approved for type 2 diabetes mellitus[J]. Expert Opin Pharmacother, 2015, 16(15): 2331-2341.
[13] TATTERSALL R.Alpha-glucosidase inhibition as an adjunct to the treatment of type 1 diabetes[J]. Diabet Med, 1993, 10(8): 688-693.
[14] DIMITRIADIS GD, TESSARI P, GO VL, et al.alpha-Glucosidase inhibition improves postprandial hyperglycemia and decreases insulin requirements in insulin-dependent diabetes mellitus[J]. Metabolism, 1985, 34(3): 261-265.
[15] YUKINA M, NURALIEVA N, SOLOVYEV M, et al.Insulin autoimmune syndrome[J]. Endocrinol Diabetes Metab Case Rep, 2020 Jun 4, 2020: 190159.
[16] OAK S, PHAN TH, GILLIAM LK, et al.Animal insulin therapy induces a biased insulin antibody response that persists for years after introduction of human insulin[J]. Acta Diabetol, 2010, 47(2):131-135.
[17] ISHIZUKA T, OGAWA S, MORI T, et al.Characteristics of the antibodies of two patients who developed daytime hyperglycemia and morning hypoglycemia because of insulin antibodies[J]. Diabetes Res Clin Pract, 2009, 84(2):e21-e23.
[18] VAN HAEFTEN TW.Clinical significance of insulin antibodies in insulin-treated diabetic patients[J]. Diabetes Care, 1989, 12(9): 641-648.
[19] IONESCU-TÎRGOVIŞTE C, MINCU I, SIMIONESCU L, et al. Disappearance rate of insulin antibodies after discontinuing insulin treatment in 42 type 2 (non-insulin-dependent) diabetic patients[J]. Diabetologia, 1984, 27(6):592-595.
[20] SHEN Y, SONG X, REN Y.Insulin autoimmune syndrome induced by exogenous insulin injection: a four-case series[J]. BMC Endocr Disord, 2019, 19(1): 148.
[21] QUAN H, TAN H, LI Q, et al.Immunological hypoglycemia associated with insulin antibodies induced by exogenous insulin in 11 Chinese patients with diabetes[J]. J Diabetes Res, 2015, 2015: 1-9.
[22] BODE BW.Comparison of pharmacokinetic properties, physicochemical stability, and pump compatibility of 3 rapid-acting insulin analogues-aspart, lispro, and glulisine[J]. Endocr Pract, 2011, 17(2): 271-280.

Pharmaceutical care for a case of fulminant type 1 diabetes with insulin allergy and positive insulin autoantibodies

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

[1]	ZHANG Xialan, YUAN Jing, WU Bin, QIN Yuanyuan. Medications of apatinib mesylate in patients with malignant tumors [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 927-932.
[2]	WANG Ran, LI Yifan, LIU Xiaoyan, FENG Xin. One case of pharmaceutical care of drug exposure during pregnancy [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 933-934.
[3]	LIU Jing, XIA Liang, ZHANG Shijie. Pharmaceutical care of a patient with acute pancreatitis complicated with multiple drug allergy undergoing drug stimulation test [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 822-824.
[4]	WANG Ran, FENG Xin, DU Boran. Advances in risk assessment and pharmaceutical care of pregnancy medication exposure during perinatal period [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 836-840.
[5]	HUO Peiqiong, ZHENG Peng, SU Zhenhao. Pharmacovigilance in retail pharmacies for special or major diseases [J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 428-432.
[6]	YANG Yan, ZHOU Dexi, WU Xinli, XUE Shuya, DING Haihua, ZHANG Quan, ZHANG Yunling. Eighty-four cases of adverse drug reactions caused by novel anti-tumor drugs [J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 334-338.
[7]	YAO Xin, GE Qiuge, LI Yamin, WANG Yifan, LI Yuanyuan, LIU Zhiqiang. Adverse drug reactions caused by new anti-tumor drugs from 2018 to 2022 in one hospital [J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1273-1278.
[8]	ZHENG Jinfeng, WANG Jinghong. Pharmaceutical care of one case of malignant arrhythmia induced by multidrug combination [J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1279-1281.
[9]	SU Su, WU Shiqi, ZHANG Qingxia, YAN Suying. Pharmaceutical care of a patient with indapamide-induced agranulocytosis [J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1282-1285.
[10]	WANG Yanting, ZHANG Yuanyuan, CHEN Yiran, SUN Jie, ZHU Yu, YANG Liyan, WU Zhigui, SHEN Lijun, CHENG Min, LI Guohui. Balanced decision between anti-infective and antitumor therapies and pharmaceutical care for a malignant tumor patient [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1168-1172.
[11]	WANG Qiru, ZUO Li, DU Qiong, YE Ling, RUAN Cong, ZHAI Qing, XU Rui. Pharmaceutical care of a patient with grade Ⅳ myelosuppression induced by olapalil [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1176-1180.
[12]	SUN Xuelin, ZHANG Pan, HU Xin. Pharmaceutical care of a case of severe ulcerative colitis treated with vedolizumab [J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 782-785.
[13]	TANG Jingya. Pharmaceutical care by a clinical pharmacists in the treatment of parenteral nutrition related hepatic damage: a case report [J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 786-788.
[14]	LI Yanming, ZHAO Zhigang. Evidence-based ibrutinib-related adverse reactions and pharmaceutical care [J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 807-811.
[15]	LYU Jintao, ZHANG Xiaomeng, ZHANG Bing, JIANG Hao, LIN Zhijian. Chinese medicine pharmacovigilance and pharmaceutical care for progestational, pregnant and post-partum women based on ancient literature [J]. Chinese Journal of Pharmacovigilance, 2022, 19(6): 585-590.